Nonsmall-cell lung cancer gemcitabine

Scalliet P, Goor C, Galdermans D, et al. Gemzar (Gemcitabine) with thoracic radiotherapy—A phase II pilot study in chemonaive patients with advanced nonsmall-cell lung cancer (NSCLC). Pro Am Soc Clin Oncol 1998 17 abstract 1923. 

Gemcitabine Gemzar Carcinoma of the pancreas nonsmall cell lung cancer Blood disorders (anemia, leukopenia, neutropenia, thrombocytopenia] dyspnea edema fever skin rash hematuria Gl distress (nausea, vomiting, constipation, diarrhea]... 

Abratt RP, Bezwoda WR, Ealkson G, et al. Efficacy and safety profile of gemcitabine in nonsmall cell lung cancer A phase 11 study. J Clin Oncol 1994 12 1535-1540. 

Kelly K, Mikhaeel-Kamel N, Pan Z, et al. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced nonsmall cell lung cancer. Clin Cancer Res 2000 6 3474-3479. 

Gemcitabine (2, 2 difluorodeoxycytidine dFdC), a di-fluoro analog of deoxycytidine, has become an important drug for patients with metastatic pancreatic cancer nonsmall-cell lung cancer and ovarian, bladder, esophageal, and head and neck cancer. 

Vansteenkiste J, Canon JL, Riska H, et al. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic nonsmall-cell lung cancer. Invest New Drugs 2005 23 263-269. 

Gemcitabine is indicated in the treatment of breast, pancreatic, and nonsmall cell lung cancers. Cytarabine, which can be administered subcutaneously and intrathecally in addition to IV, is used in the treatment of various leukemias. A liposomal formulation of cytarabine is available for the treatment of lymphomatous meningitis. 

---